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Clinical factors may influence endometrial cancer survival outcomes. We examined the
prognostic significance of age, body mass index (BMI), and type 2 diabetes among molecu-
lar subgroups of endometrial cancer.
Methods
This was a single institution retrospective study of patients who underwent surgery for endo-
metrial carcinoma between January 2007 and December 2012. Tumors were classified into
four molecular subgroups by immunohistochemistry of mismatch repair (MMR) proteins and
p53, and sequencing of polymerase-� (POLE). Overall, cancer-related, and non-cancer-
related mortality were estimated using univariable and multivariable survival analyses.
Results
Age >65 years was associated with increased mortality rates in the whole cohort (n = 515)
and in the “no specific molecular profile” (NSMP) (n = 218) and MMR deficient (MMR-D) (n =
191) subgroups during a median follow-up time of 81 months (range 1–136). However, haz-
ard ratios for cancer-related mortality were non-significant for NSMP and MMR-D. Diabetes
was associated with increased overall and non-cancer-related mortality in the whole cohort
and MMR-D subgroup. Overweight/obesity had no effect on outcomes in the whole cohort,
but was associated with decreased overall and cancer-related mortality in the NSMP sub-
group, and increased overall and non-cancer-related mortality in the MMR-D subgroup.
Overweight/obesity effect on cancer-related mortality in the NSMP subgroup remained
unchanged after controlling for confounders. High-risk uterine factors were more common,
and estrogen and progesterone receptor expression less common in NSMP subtype can-
cers of normal-weight patients compared with overweight/obese patients. No clinical factors
were associated with outcomes in p53 aberrant (n = 69) and POLE mutant (n = 37) sub-
groups. No cancer-related deaths occurred in the POLE mutant subgroup.
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Conclusions
The prognostic effects of age, BMI, and type 2 diabetes do not appear to be uniform for the
molecular subgroups of endometrial cancer. Our data support further evaluation of BMI
combined with genomics-based risk-assessment.
Introduction
Endometrial cancer is the most common gynecologic malignancy in developed countries, with
an incidence of 10 to 16 cases per 100,000 women in Western and Northern Europe [1]. Old
age has a negative impact on the survival of endometrial cancer patients [2, 3]. Compared with
younger patients, those>65 years have poorer overall survival and disease-specific survival
whether or not they underwent lymphadenectomy, and irrespective of the presence of nodal
metastasis [2]. Age�60 years is an independent predictor of locoregional relapses and disease-
related death in stage I endometrial cancer [3]. In contrast, reports on the prognostic signifi-
cance of body mass index and diabetes in endometrial cancer are inconsistent, as summarized
in several meta-analyses [4–6]. The heterogeneous results may be explained by a number of
factors, including differences in study design and selection of study subjects, methods of body
mass index and diabetes assessment, lack of power, and choice of the outcome of interest. By
merely assessing overall survival, the impact of potential risk factors on cancer-related survival
may be unrecognized.
Earlier prognostic studies [2–6] were mostly conducted prior to the development of the
molecular classification system for endometrial cancer [7]; therefore, they did not address the
role of molecular subgroups in modifying the prognostic effect of clinical factors. The molecu-
lar classification system, identified through The Cancer Genome Atlas (TCGA), categorizes
endometrial cancers into four distinct subgroups: polymerase-� (POLE) ultramutated; micro-
satellite unstable hypermutated; copy-number low; and copy-number high. This categorization
is based on: overall mutational burden; p53, POLE, and phosphatase and tensin homolog
(PTEN) mutations; microsatellite instability; and histology [7]. Molecular subgroups are asso-
ciated with different prognoses, so that: POLE ultramutated tumors have an excellent progres-
sion-free survival, microsatellite unstable hypermutated and copy-number low tumors an
intermediate progression-free survival; and copy-number high tumors a poor progression-free
survival [7].
Given the fact that the molecular subgroups can be considered to be different disease enti-
ties, each subgroup should ideally be investigated separately in clinical research studies. Based
on the putative role of clinical factors in determining the prognosis of endometrial cancer, we
wanted to examine the association of age, body mass index, and type 2 diabetes with patient
outcomes among the different molecular subgroups.
Materials and methods
Study population and data collection
Patients underwent surgical treatment for stage I–IV endometrial carcinoma at the Depart-
ment of Obstetrics and Gynecology, Helsinki University Hospital, between January 1, 2007
and December 31, 2012. Standard surgery included total hysterectomy and bilateral salpingo-
oophorectomy. Lymphadenectomy was performed in selected patients. Adjuvant therapy was
tailored according to stage and histologic findings at surgery. Patients with early-stage endo-
metrioid carcinoma with high-risk features generally received either vaginal brachytherapy or
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whole pelvic radiotherapy. Vaginal brachytherapy was mainly limited to patients in whom sur-
gical nodal assessment was performed. Patients with non-endometrioid or advanced-stage
endometrioid carcinoma received multimodality treatment with chemotherapy and radiation.
Paclitaxel/carboplatin doublet was the standard chemotherapy regimen.
Clinicopathologic data were abstracted from institutional medical and pathology records.
Weight and height were recorded at the time of endometrial cancer diagnosis. Overweight and
obesity were specified as a body mass index 25–29.9 kg/m2 and�30 kg/m2, respectively,
according to the World Health Organization (WHO) definitions. WHO class III obesity was
defined as a body mass index�40 kg/m2. Information on diabetes mellitus was captured by
patient intake history at the time of initial consultation. Stage was determined according to the
International Federation of Gynecology and Obstetrics guidelines revised in 2009 [8]. The cut-
off for age was based on the finding that age >65 years is an independent poor prognostic fac-
tor in endometrial cancer [2]. The choice of 5 cm as a determinant for the analysis of tumor
size was based on earlier literature according to which size approximating the entire uterine
cavity is strongly associated with survival in stage I endometrial cancer [9]. Lymphovascular
space invasion was defined as the presence of adenocarcinoma, of any extent, in endothelium-
lined channels of uterine specimens outside the tumor.
Cause of death was mainly based on medical records. Missing data were complemented
from death certificates. The study was approved by the local institutional review board and the
National Supervisory Authority for Welfare and Health. Informed consent was waived because
of the retrospective nature of the study.
Molecular classification
Tumors were categorized into molecular subgroups according to the TransPORTEC classifier
that recapitulates the four molecular subgroups of the TCGA as follows: “no specific molecular
profile” (NSMP, surrogate to copy-number low in the TCGA classification system); mismatch
repair deficient (MMR-D, surrogate to microsatellite unstable hypermutated); p53 abnormal
(p53 abn, surrogate to copy-number high); and POLE mutant [10]. Minor adjustments were
introduced to the TransPORTEC protocol. First, while our p53 and microsatellite instability
analyses were solely based on immunohistochemistry, the TransPORTEC classifier uses a
combination of TP53 mutational testing and p53 immunohistochemistry to determine p53 sta-
tus, and primarily the Promega microsatellite instability analysis for determination of micro-
satellite instability status. For tumors exhibiting low levels of instability, or from which
extracted DNA quality is poor, immunohistochemistry of MMR proteins is performed. Sec-
ond, the TransPORTEC classifier detects POLE exonuclease domain hotspot mutations by
Sanger sequencing of exons 9 and 13, whereas we performed sequencing of exons 9, 13, and
14. Lastly, we did not exclude cases with multiple classifying alterations. Instead, they were cat-
egorized according to the alteration that determines the clinical outcome [11, 12].
Patients with adequate tumor samples for a tissue microarray were eligible for the study.
For the construction of tissue microarray, histologic slides were reviewed by a pathologist and
representative areas of each tumor were marked on the slides. Four duplicate 0.8 mm cores
were drawn from the corresponding area of the paraffin blocks and a tissue microarray block
was prepared. The following monoclonal antibodies were used for chromogenic immunohis-
tochemistry: MLH1 (ES05, Dako, Santa Clara, CA, USA); MSH2 (G219-1129, BD Biosciences,
San Jose, CA, USA); MSH6 (EPR3945, Abcam, Cambridge, UK); PMS2 (EPR3947, Epitomics,
Burlingame, CA, USA); and p53 (DO-7, Dako). Tissue microarray slides were scanned with
three-dimensional Histech Pannoramic 250 Flash II scanner by Fimmic Oy (Helsinki, Fin-
land). Slide images were managed and analyzed with WebMicroscope Software (Fimmic Oy).
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Virtual slides were scored by a pathologist blinded to clinical data. A second investigator exam-
ined equivocal cases and a consensus was reached. MMR protein status was considered defi-
cient when we observed a complete loss of nuclear expression in carcinoma cells of one or
more MMR proteins (MLH1, MSH2, MSH6, PMS2) detected by immunohistochemistry.
Aberrant p53 staining was defined as strong and diffuse nuclear staining or completely nega-
tive (‘null’) staining in carcinoma cells. Weak and heterogeneous staining was classified as
wild-type expression. Stromal cells and inflammatory cells served as internal controls for
MMR and p53 stainings. Samples with scarce carcinoma cells or completely negative staining
of the internal controls, when applicable, were discarded.
For DNA extraction, representative areas of formalin-fixed paraffin-embedded tumor tissue
were macrodissected as identified by pathologist assessment. DNA was extracted by proteinase
K/phenol-chloroform method. POLE exonuclease domain mutation (EDM) screening of hot
spots in exon 9 (c.857C>G, p.P286R; c.890C>T, p.S297F), exon 13 (c.1231G>C, p.V411L),
and exon 14 (c.1366G>C, p.A456P) was performed by direct sequencing. The following prim-
ers were used: Ex 9F (5’–3’): CCTAATGGGGAGTTTAGAGCTT; Ex 9R (5’–3’): CCCATCCCAG
GAGCTTACTT; Ex 13F (5’–3’): TCTGTTCTCATTCTCCTTCCAG; Ex 13R (5’–3’): CGGGAT
GTGGCTTACGTG; Ex 14F (5’–3’): TGACCCTGGGCTCTTGATTT; Ex 14R (5’–3’): ACAGGACA
GATAATGCTCACC. Polymerase chain reaction products were sequenced on an ABI3730XI
Automatic DNA Sequencer (Applied Biosystems, Foster City, CA, USA). Sequence graphs
were analyzed both manually and with Mutation Surveyor (Softgenetics, State College, PA,
USA). Only cases with good-quality sequence for all the examined four POLE hot spots were
included in the analysis.
For further characterization, the following monoclonal antibodies were used for chromo-
genic immunohistochemistry on multicore tissue microarray slides: estrogen receptor-α (SP1,
Roche/Ventana, Oro Valley, AZ, USA); progesterone receptor (clone 16, Novocastra, Newcas-
tle upon Tyne, UK); and L1 cell adhesion molecule (L1CAM, clone 14.10, Covance, Princeton,
NJ, USA). The cut-off for positive estrogen and progesterone receptor expression was set at
10% based on endometrial cancer and breast cancer studies [13–15]. For L1CAM expression,
�10% of membranous staining was considered positive [16–18].
Statistical methods
Chi-squared test was used for comparison of categorical variables, and analysis of variance and
Kruskal-Wallis test for comparison of continuous variables after testing for normality by Sha-
piro-Wilk test. Hazard ratios for overall mortality, cancer-related mortality, and non-cancer-
related mortality were estimated using univariable and multivariable Cox regression analyses.
Cancer-related mortality was the main outcome measure. Variables with proven prognostic
significance were entered as covariates in the multivariable model. These included stage [19],
features of the primary tumor [20, 21], estrogen and progesterone receptor expression [13, 14,
22], L1CAM expression [16–18, 23], and adjuvant therapy [24]. Survival times were estimated
using the Kaplan-Meier method. Differences between groups were compared using the log
rank test. Survivals were calculated as the times from surgery to death. Statistical significance
was set at P< 0.05. Data were analyzed using the Statistical Package for the Social Sciences ver-
sion 25 software (IBM Corp., Armonk, NY, USA).
Results
A total of 515 endometrial carcinomas were classified into molecular subgroups. Twenty cases
(3.9%) displayed multiple molecular features. Three cases displayed POLE EDM and either
MMR-D or p53 abn, and one case had all three molecular alterations. These were classified as
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POLE EDM tumors [12]. Sixteen cases, classified as MMR-D tumors [11], displayed both
MMR-D and p53 abn. The basic characteristics of the study population are summarized in
Table 1. We found that POLE EDM is associated with younger age and lower body mass index,
whereas p53 abn is associated with older age. The prevalence of type 2 diabetes was similar
between molecular subgroups.
Median follow-up time was 81 months (range 1–136). During follow-up a total of 160
patients died, including 97 deaths related to endometrial cancer (Table 2).
Univariable Cox regression analyses were performed separately for overall mortality, can-
cer-related mortality, and non-cancer-related mortality (Table 2). Associations of clinical
Table 1. Characteristics of the study population according to molecular subgroups.
NSMP (n = 218) POLE EDM (n = 37) MMR-D (n = 191) p53 abn (n = 69) P
Age (years) [median (interquartile range)] 66 (60−73) 59 (53−68) 70 (61−77) 72 (66−78) <0.0005
Age >65 years 116 (53.2%) 11 (29.7%) 121 (63.4%) 52 (75.4%) <0.0005
Body mass index (kg/m2) [median (interquartile range)] 28.5 (24.3−33.2) 25.1 (23.0−28.3) 27.1 (23.3−32.7) 27.3 (24.4−30.5) 0.023
Overweight/obese 157 (72.0%) 21 (56.8%) 118 (61.8%) 45 (65.2%) 0.091
World Health Organization class III obesity 14 (6.4%) 1 (2.7%) 7 (3.7%) 3 (4.3%) 0.541
Type 2 diabetes 40 (18.3%) 4 (10.8%) 37 (19.4%) 13 (18.8%) 0.671
Pelvic lymphadenectomy 129 (59.2%) 23 (62.2%) 106 (55.5%) 32 (46.4%) 0.255
Pelvic-aortic lymphadenectomy 19 (8.7%) 5 (13.5%) 34 (17.8%) 22 (31.9%) <0.0005
Stage <0.0005
IA 123 (56.4%) 28 (75.7%) 84 (44.0%) 22 (31.9%)
IB 42 (19.3%) 6 (16.2%) 44 (23.0%) 18 (26.1%)
II 23 (10.6%) 2 (5.4%) 19 (9.9%) 1 (1.4%)
IIIA 9 (4.1%) 1 (2.7%) 13 (6.8%) 5 (7.2%)
IIIB 1 (0.5%) 0 (0%) 2 (1.0%) 1 (1.4%)
IIIC1 13 (6.0%) 0 (0%) 18 (9.4%) 3 (4.3%)
IIIC2 1 (0.5%) 0 (0%) 7 (3.7%) 9 (13.0%)
IVA 0 (0%) 0 (0%) 0 (0%) 0 (0%)
IVB 6 (2.8%) 0 (0%) 4 (2.1%) 10 (14.5%)
Histology <0.0005
Endometrioid carcinoma 206 (94.5%) 34 (91.9%) 174 (91.1%) 36 (52.2%)
Clear cell carcinoma 5 (2.3%) 2 (5.4%) 5 (2.6%) 13 (18.8%)
Serous carcinoma 2 (0.9%) 1 (2.7%) 3 (1.6%) 11 (15.9%)
Carcinosarcoma 2 (0.9%) 0 (0%) 3 (1.6%) 7 (10.1%)
Undifferentiated carcinoma 3 (1.4%) 0 (0%) 6 (3.1%) 2 (2.9%)
Grade (For endometrioid only; n = 450) <0.0005
1 141 (68.4%) 21 (61.8%) 79 (45.4%) 5 (13.9%)
2 52 (25.2%) 8 (23.5%) 54 (31.0%) 15 (41.7%)
3 13 (6.3%) 5 (14.7%) 41 (23.6%) 16 (44.4%)
Adjuvant therapy <0.0005
None 33 (15.1%) 6 (16.2%) 20 (10.5%) 7 (10.1%)
Vaginal brachytherapy 116 (53.2%) 22 (59.5%) 83 (43.5%) 18 (26.1%)
Pelvic radiotherapy 28 (12.8%) 6 (16.2%) 35 (18.3%) 12 (17.4%)
Chemotherapy 7 (3.2%) 0 (0%) 8 (4.2%) 7 (10.1%)
Chemotherapy and vaginal brachytherapy 10 (4.6%) 0 (0%) 10 (5.2%) 11 (15.9%)
Chemotherapy and pelvic radiotherapy 24 (11.0%) 3 (8.1%) 35 (18.3%) 14 (20.3%)
Abbreviations: MMR-D, mismatch repair deficient; NSMP, no specific molecular profile; POLE EDM, polymerase-� exonuclease domain mutation; p53 abn, p53
abnormal.
https://doi.org/10.1371/journal.pone.0242733.t001
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factors with the outcomes were first examined in the whole cohort. Old age (>65 years) was
invariably associated with poor outcomes. Overweight/obesity (body mass index�25 kg/m2)
was not associated with any of the outcomes, whereas type 2 diabetes was associated with
increased overall mortality and non-cancer-related mortality.
Associations were then examined separately for each molecular subgroup (Table 2). Old
age was associated with increased overall mortality and non-cancer-related mortality in NSMP
and MMR-D subgroups. Overweight/obesity and type 2 diabetes were associated with
increased overall mortality and non-cancer-related mortality in the MMR-D subgroup. In the
NSMP subgroup, overweight/obesity was associated with decreased overall mortality and can-
cer-related mortality, our main outcome of interest. For POLE EDM and p53 abn, significant
associations between clinical factors and outcomes were not observed. Hazard ratios for can-
cer-related mortality were not calculable in the POLE EDM subgroup because there were no
cancer-related deaths in this subgroup of patients.
Kaplan-Meier disease-specific survival analyses were performed separately for three body
mass index categories in the NSMP subgroup. Disease-specific survival was similarly improved
for overweight patients (body mass index 25−29.9 kg/m2) and obese patients (body mass index
�30 kg/m2) compared with normal-weight patients (body mass index<25 kg/m2) (Fig 1).
Body mass index 25 kg/m2 was therefore selected as the cut-off for further analyses.
Table 3 shows the proportions of various prognostic variables in normal-weight and over-
weight/obese patients with NSMP subtype cancer. High-risk histology, deep myometrial inva-
sion (�50%), and lymphovascular space invasion were more common in normal-weight
compared with overweight/obese patients. Moreover, estrogen and progesterone receptor
Table 2. Univariable Cox regression analyses of overall, cancer-related and non-cancer-related mortality.
Mortality All NSMP POLE EDM MMR-D p53 abn
(n = 515) (n = 218) (n = 37) (n = 191) (n = 69)
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Age >65 Years Overall † 2.7 (1.9−3.9)
P < 0.0005
2.8 (1.4−5.5) P = 0.004 4.6 (0.42−51) P = 0.212 2.6 (1.5−4.4) P = 0.001 0.95 (0.45−2.0)
P = 0.900




















1.8 (1.1−3.0) P = 0.018 0.65 (0.34−1.2)
P = 0.190
















3.1 (1.3−7.5) P = 0.013 0.56 (0.16−1.9)
P = 0.364
Type 2 diabetes Overall † 1.5 (1.1−2.2) P = 0.019 0.87 (0.39−1.9)
P = 0.729




















† N deaths = 160 (n = 43, n = 3, n = 76 and n = 38 for NSMP, POLE EDM, MMR-D and p53 abn, respectively)
‡ N deaths = 97 (n = 25, n = 0, n = 44 and n = 28 for NSMP, POLE EDM, MMR-D and p53 abn, respectively).
§ N deaths = 63 (n = 18, n = 3, n = 32 and n = 10 for NSMP, POLE EDM, MMR-D and p53 abn, respectively).
Abbreviations: CI, confidence interval; HR, hazard ratio; MMR-D, mismatch repair deficient; NSMP, no specific molecular profile; POLE EDM, polymerase-�
exonuclease domain mutation; p53 abn, p53 abnormal.
https://doi.org/10.1371/journal.pone.0242733.t002
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expression was less common in normal-weight patients. L1CAM expression and proportions
of old patients (>65 years), stage II−IV cancers, large tumors (>5 cm), and adjuvant therapies
received were not significantly different for normal-weight and overweight/obese patients.
Fig 1. Kaplan-Meier disease-specific survival analyses concerning body mass index in the “no specific molecular profile” subgroup.
https://doi.org/10.1371/journal.pone.0242733.g001
Table 3. Proportions of various prognostic variables in normal-weight and overweight/obese patients with “no specific molecular profile” subtype endometrial
cancer.
Normal-weight (n = 61) Overweight/obese (n = 157) P
Age >65 years 33 (54.1%) 83 (52.9%) 0.870
Stage II−IV 18 (29.5%) 35 (22.3%) 0.265
Histology <0.0005
Endometrioid grade 1−2 carcinoma 44 (72.1%) 149 (94.9%)
Endometrioid grade 3 carcinoma 9 (14.8%) 4 (2.5%)
Non-endometrioid carcinoma 8 (13.1%) 4 (2.5%)
Myometrial invasion�50% 30 (49.2%) 53 (33.8%) 0.035
Tumor size >5 cm † 17 (28.8%) 27 (18.9%) 0.120
Lymphovascular space invasion 21 (34.4%) 28 (17.8%) 0.008
Estrogen receptor expression ‡ 48 (80.0%) 143 (94.1%) 0.002
Progesterone receptor expression § 40 (66.7%) 139 (89.1%) <0.0005
L1 cell adhesion molecule expression ¶ 6 (10.3%) 8 (5.3%) 0.187
Adjuvant therapy 0.537
None or vaginal brachytherapy 39 (63.9%) 110 (70.1%)
Pelvic radiotherapy 7 (11.5%) 21 (13.4%)
Chemotherapy 7 (11.5%) 10 (6.4%)
Chemotherapy and pelvic radiotherapy 8 (13.1%) 16 (10.2%)
† Data missing for 2 normal-weight and 14 overweight/obese patients
‡ data missing for 1 normal-weight and 5 overweight/obese patients
§ data missing for 1 normal-weight and 1 overweight/obese patient
¶ data missing for 3 normal-weight and 5 overweight/obese patients.
https://doi.org/10.1371/journal.pone.0242733.t003
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To assess the contribution of various clinicopathologic variables to patient outcome in the
NSMP subgroup, we performed univariable and multivariable Cox regression analyses of can-
cer-related mortality (Table 4). All of the tested variables, i.e. overweight/obesity, stage, fea-
tures of the primary tumor, estrogen and progesterone receptor expression, L1CAM
expression, and adjuvant therapy, were associated with cancer-related mortality in unadjusted
analyses. In the multivariable model, only overweight/obesity was found to have a significant
independent effect on the outcome.
Discussion
We explored the variation and prognostic significance of age, overweight/obesity, and type 2
diabetes in 515 women with endometrial carcinoma that were classified into molecular sub-
groups by immunohistochemistry of MMR proteins and p53, as well as POLE sequencing. Old
age, overweight/obesity, and type 2 diabetes in the MMR-D subgroup, and old age in the
NSMP subgroup were associated with increased overall mortality and non-cancer-related
mortality. Overweight/obesity was associated with decreased overall mortality and cancer-
related mortality in the NSMP subgroup. POLE EDM was associated with younger age and
lower body mass index, whereas p53 abn was associated with older age, in accordance with
previous studies [25–27]. For these subgroups, significant associations between clinical factors
and outcomes were not observed. Hazard ratios for cancer-related mortality were not calcula-
ble in the POLE EDM subgroup because there were no cancer-related events in this subgroup
of patients. Clinicopathologic characteristics generally varied among subgroups, which can be
Table 4. Univariable and multivariable Cox regression analyses of cancer-related mortality for the “no specific molecular profile” subgroup.
Univariable (n = 218) Multivariable (n = 186)
N deaths = 25 N deaths = 20
N (%) HR (95% CI) P HR (95% CI) P
Overweight/obese 157 (72.0%) 0.32 (0.15−0.71) 0.005 0.32 (0.11−0.92) 0.034
Stage II-IV 53 (24.3%) 5.3 (2.4−12) <0.0005 6.1 (0.97−39) 0.053
Histology <0.0005 0.425
Endometrioid grade 1−2 carcinoma 193 (88.5%) 1 1
Endometrioid grade 3 carcinoma 13 (6.0%) 14 (5.6−33) <0.0005 3.2 (0.49−20) 0.228
Non-endometrioid carcinoma 12 (5.5%) 6.6 (2.2−20) 0.001 1.4 (0.19−10) 0.736
Myometrial invasion�50% 83 (38.1%) 5.7 (2.3−14) <0.0005 2.9 (0.68−12) 0.153
Tumor size >5 cm † 44 (21.8%) 3.8 (1.7−8.4) 0.001 1.4 (0.38−4.8) 0.634
Lymphovascular space invasion 49 (22.5%) 5.9 (2.7−13) <0.0005 1.8 (0.58−5.4) 0.315
Estrogen receptor expression ‡ 191 (90.1%) 0.14 (0.063−0.32) <0.0005 0.62 (0.11−3.5) 0.587
Progesterone receptor expression § 179 (82.9%) 0.28 (0.12−0.64) 0.003 1.6 (0.42−6.3) 0.483
L1 cell adhesion molecule expression ¶ 14 (6.7%) 7.1 (2.8−18) <0.0005 3.0 (0.61−14) 0.177
Adjuvant therapy 0.012 0.273
None or vaginal brachytherapy 149 (68.3%) 1 1
Pelvic radiotherapy 28 (12.8%) 1.4 (0.40−5.2) 0.573 0.20 (0.028−1.4) 0.111
Chemotherapy 17 (7.8%) 3.8 (1.2−12) 0.022 0.78 (0.14−4.3) 0.772
Chemotherapy and pelvic radiotherapy 24 (11.0%) 4.2 (1.6−11) 0.003 0.21 (0.026−1.7) 0.141
† Data missing for 16 patients
‡ data missing for 6 patients
§ data missing for 2 patients
¶ data missing for 8 patients.
Abbreviations: CI, confidence interval; HR, hazard ratio.
https://doi.org/10.1371/journal.pone.0242733.t004
PLOS ONE Clinical factors in molecular subgroups of endometrial cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0242733 November 24, 2020 8 / 12
explained by the fact that the molecular classifier employed in this study correlates with tradi-
tional prognostic factors of endometrial cancer [10].
To better understand the effect of body mass index on cancer-related mortality in the
NSMP subgroup, we compared the proportions of various risk factors in normal-weight and
overweight/obese patients in this subgroup, and found that high-risk uterine factors were
more common in normal-weight patients. The presence of uterine risk factors is associated
with increased risk for recurrences and poor survival, even in the absence of metastatic nodal
disease [20, 21]. Lean patients in the NSMP subgroup also had a high-risk expression profile of
molecular biomarkers. Expression of estrogen and progesterone receptors, known to be associ-
ated with improved endometrial cancer-specific survival [13, 14, 22], was less common in nor-
mal-weight patients compared with overweight/obese patients. Moreover, although not
statistically significant, the expression of L1CAM, a poor prognostic factor in endometrial can-
cer [16–18, 23], was twice as common in normal-weight patients as in overweight/obese
patients. When the prognostic effects of uterine risk factors and molecular biomarkers, along
with overweight/obesity, stage and adjuvant therapy, were assessed in a multivariable model,
only overweight/obesity had an independent effect on cancer-related mortality. This empha-
sizes the prognostic strength of body mass index in the NSMP subgroup, relative to other
established risk factors.
This study is strengthened by the large sample size that allowed us to undertake analyses
stratified into the various molecular subgroups of endometrial cancer. Admittedly, however,
the smaller sizes of POLE EDM and p53 abn molecular subgroups may have precluded signifi-
cant findings of clinical factors on outcomes in these subgroups. Information on cause of
death was available for all of the deceased which allowed us to make a distinction in assessing
not only overall mortality, but also cancer-related mortality, which can be considered the ideal
outcome of interest when looking for causalities in cancer research. Knowledge of cancer-
related deaths is especially important in endometrial cancer, for which competing causes of
death are common; in the current study, 39% of deaths were secondary to causes other than
endometrial cancer. Unlike most earlier studies, we were also able to distinguish between type
1 and type 2 diabetes. This improved the assessment of the true relation between diabetes and
outcomes, as only type 2 diabetes appears to be prognostic in endometrial cancer [28].
Although our findings are limited to a single institution, the stage distribution and propor-
tion of non-endometrioid carcinomas were comparable to an unselected cohort of 5,866
patients in the Gynecologic Oncology Group 210 surgical pathological staging study, in which
the vast majority of tumors were early-stage endometrioid carcinomas [29]. The frequency of
diabetes was captured by self-report, which could potentially lead to some misclassification.
However, patient administered questionnaires, also used in our hospital, appear to be a reliable
source of information in diabetes [30]. Information on the treatment of diabetes was unavail-
able for our study, which may partly distort the results, as metformin has been shown to
improve overall survival and progression-free survival in patients with endometrial cancer
[31].
Based on the current findings, endometrial cancer subgroups described by the TCGA rep-
resent not only unique genomic subgroups, but also entities that have distinct clinical prognos-
tic features. Presuming that the proportions of molecular subgroups can vary across different
study cohorts, the earlier contradictory findings [4–6] on clinical factors as prognosticators
may be somewhat explained by the neutral effect of clinical factors on outcomes of POLE
EDM and p53 abn subgroups, and partly opposing effect on outcomes of NSMP and MMR-D
subgroups. Our findings may aid in patient counseling on the interrelation between dietary
intake and prognosis, in addition to lending support to the implementation of body mass
index in genomics-based risk-assessment. Future studies will probably show if refinement of
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genomics-based characterization can explain the different prognosis of patients with identical
molecular subgroups but unlike clinical characteristics. For example, inactivation of PTEN,
whose mutational frequency differs between TCGA subgroups [7], has been suggested to
determine the outcome of endometrial cancer patients in the context of body mass index [32,
33].
In summary, our findings suggest that the prognostic effects of old age, overweight/obesity,
and type 2 diabetes are not uniform for the molecular subgroups of endometrial cancer. Thus,
clinical factors should be assessed as prognostic variables in conjunction with the molecular
subgroup. The present data suggest that the metabolic consequences of adiposity play different
roles in the aggressiveness of endometrial cancer, depending on the molecular subtype. Fur-
ther work is needed to identify molecular pathways and prognostic biomarkers specific to
women with different clinical characteristics.
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Software: Mikko Loukovaara.
Supervision: Riitta Koivisto-Korander, Ralf Bützow, Mikko Loukovaara.
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